A new generation of non-invasive tests of liver fibrosis with improved accuracy in MASLD
Currently recommended non-invasive tests (NITs) have insufficient accuracy (<80%) for the diagnosis of advanced fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD). Therefore, we developed three new NITs with new statistical techniques. Thus, FIB-9 (available via a free calculator), including nine common blood markers, equaled the performance of patented NITs. FIB-11, adding two specialized blood markers, and FIB-12, adding liver stiffness, had accuracy >80%. FIB-12 outperformed all other NITs. FIB-9 is suitable for screening and FIB-11 or FIB-12 for diagnosis.
Authors
- Gilles Hunault (ORCID: https://orcid.org/0000-0001-9061-3609)
- Jérôme Boursier
- Charlotte E. Costentin (ORCID: https://orcid.org/0000-0001-6115-8512)
- Clémence M. Canivet (ORCID: https://orcid.org/0000-0002-1699-0278)
- Isabelle Fouchard (ORCID: https://orcid.org/0000-0002-7420-7026)
- Paul Calès (ORCID: https://orcid.org/0000-0003-4866-5274)
- Victor de Lédinghen (ORCID: https://orcid.org/0000-0001-6414-1951)
- Adrien Lannes
- Frédéric Oberti (ORCID: https://orcid.org/0000-0002-1799-8837)
Institutions
- Centre National de la Recherche Scientifique (FR)
- Université de Bordeaux (FR)
- Inserm (FR)
- Centre Hospitalier Universitaire de Grenoble (FR)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Centre Hospitalier Universitaire d'Angers (FR)
- Hôpital Cardiologique du Haut-Lévêque (FR)
- Université d'Angers (FR)
- Université Grenoble Alpes (FR)
Publication Details
- Journal
- Journal of Hepatology
- Published
- 2024-12-13
- DOI
- https://doi.org/10.1016/j.jhep.2024.11.049
- Citations
- 25
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 9.67
Funders
- Société d'Accélération du Transfert de Technologies